VIDEO: Bilateral ABBV-RGX-314 shows positive outcomes in wet AMD
Click Here to Manage Email Alerts
CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Arshad M. Khanani, MD, MA, FASRS, discusses bilateral ABBV-RGX-314 gene therapy for neovascular age-related macular degeneration.
According to Khanani, the study marks the first time that participants with neovascular AMD received a gene therapy in both eyes. The data included 10 previously treated participants dosed with a single subretinal injection of ABBV-RGX-314 (Regenxbio) in the fellow eye.
“We saw that ABBV-RGX-314 is safe and is effective,” he said.
Patients experienced a 97% reduction in treatment burden, with maintenance of visual acuity and central retinal thickness.
Collapse
Khanani AM. Subretinal delivery of investigational ABBV-RGX-314 as a gene therapy for nAMD: First time results of a fellow eye bilateral dosing study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Read more about
Click Here to Manage Email Alerts